Stock CANTA CANTARGIA AB
Add to a list
To use this feature you must be a member
Log inSign up

News Cantargia AB

Equities

CANTA

SE0006371126

Delayed Nasdaq Stockholm
Other stock markets
 11:07:18 2024-04-29 am EDT 		5-day change 1st Jan Change
3.426 SEK -0.70% Intraday chart for Cantargia AB -8.15% -8.35%
Apr. 17 Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition CI
Apr. 10 Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cantargia publishes Annual Report for 2023
AQ
Notice of annual general meeting in Cantargia AB (publ)
AQ
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition
AQ
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition
CI
Cantargia : Proposal regarding share-based incentive scheme
PU
Cantargia : Proposal regarding guidelines for executive remuneration
PU
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal
CI
Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal
AQ
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer
CI
Cantargia presents unique effects of nadunolimab in pancreatic cancer
AQ
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis
CI
Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis
AQ
Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia
AQ
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia
CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis
CI
Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis
AQ
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer
CI
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer
AQ
Cantargia Q4 2023 - Progress with CAN10 and in PDA
AQ
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CANTA Stock
  4. News Cantargia AB